2024
Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapyAn Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/metastatic breast cancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore gradeClinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj G, Vinayak S, Khaki A, Sun T, Kuderer N, Aboulafia D, Acoba J, Awosika J, Bakouny Z, Balmaceda N, Bao T, Bashir B, Berg S, Bilen M, Bindal P, Blau S, Bodin B, Borno H, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman L, Flora D, Friese C, Galsky M, Gonzalez C, Grivas P, Gupta S, Haynam M, Heilman H, Hershman D, Hwang C, Jani C, Jhawar S, Joshi M, Kaklamani V, Klein E, Knox N, Koshkin V, Kulkarni A, Kwon D, Labaki C, Lammers P, Lathrop K, Lewis M, Li X, de Lima Lopes G, Lyman G, Makower D, Mansoor A, Markham M, Mashru S, McKay R, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen R, Nonato T, O'Connor T, Panagiotou O, Park K, Patel J, Patel K, Peppercorn J, Polimera H, Puc M, Rao Y, Razavi P, Reid S, Riess J, Rivera D, Robson M, Rose S, Russ A, Schapira L, Shah P, Shanahan M, Shapiro L, Smits M, Stover D, Streckfuss M, Tachiki L, Thompson M, Tolaney S, Weissmann L, Wilson G, Wotman M, Wulff-Burchfield E, Mishra S, French B, Warner J, Lustberg M, Accordino M, Shah D. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife 2023, 12: e82618. PMID: 37846664, PMCID: PMC10637772, DOI: 10.7554/elife.82618.Peer-Reviewed Original ResearchConceptsCOVID-19 severityWorse COVID-19 outcomesCOVID-19 outcomesBreast cancerCause mortalityCohort studyAcute respiratory syndrome coronavirus 2 infectionCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionRegistry-based retrospective cohort studyHistory of BCIntensive care unit admissionNon-Hispanic white patientsSyndrome coronavirus 2 infectionWorse ECOG performance statusMultivariable ordinal logistic regression modelsCare unit admissionCoronavirus 2 infectionECOG performance statusRetrospective cohort studyPacific Islander patientsCoronavirus disease 2019American Cancer SocietyLogistic regression modelsResearch grant supportInflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition
Madison A, Andridge R, Renna M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams N, Sardesai S, Noonan A, Reinbolt R, Cherian M, Malarkey W, Kiecolt-Glaser J. Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition. Journal Of Affective Disorders 2023, 342: 1-9. PMID: 37683942, PMCID: PMC10591975, DOI: 10.1016/j.jad.2023.09.008.Peer-Reviewed Original ResearchConceptsInflammatory cytokine responseCytokine responsesCancer survivorsTyphoid vaccineConners' Continuous Performance TestPostmenopausal breast cancer survivorsInterleukin-1 receptor antagonistResponse inhibitionBreast cancer survivorsInterleukin-6 responseSaline placebo injectionsOutcomes of interestPolysaccharide vaccinationPlacebo injectionsCrossover trialReceptor antagonistSeparate visitsContinuous Performance TestSecondary analysisAspects of impulsivityPlaceboNon-significant resultsPrepotent response inhibitionVaccineInjectionBiomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data
Lantis K, Schnell P, Bland C, Wilder J, Hock K, Vargo C, Glover N, Hackney M, Lustberg M, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials 2023, 24: 564. PMID: 37658464, PMCID: PMC10472642, DOI: 10.1186/s13063-023-07554-z.Peer-Reviewed Original ResearchConceptsChemotherapy-induced neuropathyPhysical activityBackgroundBreast cancerOutcome measuresNon-pharmacologic interventionsBreast cancer survivorsPrimary outcome measureHome exercise interventionQuality of lifeControl intervention groupPreliminary baseline dataPrimary endpointExercise interventionBC survivorsTertiary outcomesCancer survivorsSensorimotor symptomsClinical trialsIntervention groupTwo-armWeek 8Mean changeFall riskPrimary estimandTreatment groupsFemale reproductive health in pediatric, adolescent, and young adult cancer survivors
Hoefgen H, Benoit J, Chan S, Jayasinghe Y, Lustberg M, Pohl V, Saraf A, Schmidt D, Appiah L. Female reproductive health in pediatric, adolescent, and young adult cancer survivors. Pediatric Blood & Cancer 2023, 70: e29170. PMID: 37381166, DOI: 10.1002/pbc.29170.Peer-Reviewed Original ResearchConceptsQuality of lifeGenital graftHost diseaseCancer survivorsLate effectsReproductive healthHematopoietic stem cell transplantCancer treatmentYoung adult cancer survivorsHormone replacement therapyCervical cancer screeningStem cell transplantFemale reproductive healthAdult cancer survivorsLarge cohort studyLikelihood of pregnancyYoung Adult Cancer SurvivorshipAdult cancer survivorshipGynecologic outcomesVaginal injuryCohort studyCell transplantReplacement therapyCancer careCancer screeningWorry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial
Renna M, Madison A, Peng J, Shrout M, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen J, Williams N, Sardesai S, Noonan A, Reinbolt R, Stover D, Cherian M, Malarkey W, Andridge R, Kiecolt-Glaser J. Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial. Annals Of Behavioral Medicine 2023, 57: 888-898. PMID: 37335884, PMCID: PMC10498820, DOI: 10.1093/abm/kaad032.Peer-Reviewed Original ResearchConceptsEmotion regulationMemory problemsCognitive tasksBreast cancer survivorsEmotion regulation abilitiesAdaptive emotion regulationEmotion regulation skillsHigher subjective fatigueSubjective memory problemsCancer survivorsCognitive side effectsPain sensitivityRegulation skillsLow mindfulnessCognitive problemsMindfulness QuestionnaireRegulation abilitySubjective fatiguePhysical healthBreast cancer survivorshipCold pain sensitivityObjective ratingsConcentration problemsMindfulnessInflammatory responseQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin useA troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship
Madison A, Filatov M, Andridge R, Haas G, Povoski S, Agnese D, Lustberg M, Reinbolt R, Wesolowski R, Williams N, Malarkey W, Kiecolt-Glaser J. A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship. PLOS ONE 2023, 18: e0283849. PMID: 37000800, PMCID: PMC10065250, DOI: 10.1371/journal.pone.0283849.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMood disorder historyExercise stress testCancer survivorsCardiovascular diseaseDisorder historyDepressive symptomsTreatment typeEpidemiologic Studies Depression ScaleNon-cancer causesBreast cancer survivorshipStructured Clinical InterviewAdvanced cancer treatmentStress testCardiotoxic treatmentsAdjuvant treatmentCross-sectional relationshipAntidepressant useTrunk fatCVD developmentVisit 1Depression ScaleCancer survivorshipPhysical activityClinical InterviewConflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases
Madison A, Renna M, Andridge R, Peng J, Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams N, Noonan A, Reinbolt R, Stover D, Cherian M, Malarkey W, Kiecolt-Glaser J. Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases. Pain 2023, 164: 1985-1994. PMID: 36943254, PMCID: PMC10440304, DOI: 10.1097/j.pain.0000000000002894.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsChronic social stressPostmenopausal breast cancer survivorsInterleukin-1 receptor antagonistSocial stressEffects of inflammationAcute inflammatory responseSaline placeboChronic painElevated painMore painReceptor antagonistInterleukin-6Inflammatory responseHours postinjectionDepression riskPainInflammatory increasesNervous systemSeparate visitsNonsocial stressVaccine sequenceBehavioral covariatesInflammationHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancerIdentification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Supportive Care In Cancer 2023, 31: 139. PMID: 36707490, DOI: 10.1007/s00520-023-07595-9.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyLarge cooperative group trialsCooperative group trialsIndependent patient cohortsCancer chemotherapy regimenCIPN riskCommon toxicitiesTaxane exposureChemotherapy regimenNeuropathy riskPeripheral neuropathyPatient cohortClinical trialsBreast cancerGroup trialsEffective interventionsPatientsRisk determinationInconsistent resultsECoGTrialsPresent studyRiskDiscriminatory powerHigh predictive accuracyRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2022
Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study
Yang Y, McLaughlin E, Naughton M, Lustberg M, Nolan T, Kroenke C, Weitlauf J, Saquib N, Shadyab A, Follis S, Pan K, Paskett E. Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study. Supportive Care In Cancer 2022, 31: 48. PMID: 36525119, PMCID: PMC9758078, DOI: 10.1007/s00520-022-07505-5.Peer-Reviewed Original ResearchConceptsWomen's Health Initiative (WHI) LifeBreast cancerMedian cognitive scoresCognitive functionCognitive scoresBreast cancer stage IMedical Outcomes Study Social Support SurveySocial supportCognitive functioningCancer stage IHigher social support scoresSocial Support SurveyMultivariable quantile regressionHigher cognitive functioningNon-Hispanic whitesSelf-reported cognitive functioningSocial support scoresMajority of participantsBaseline questionnaireCancer cohortHigh riskMethodsThe studyKruskal-Wallis testStage IHigh social supportTreatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2021
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: 300-312. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationBreast cancer patientsBreast cancer diagnosisAtrial fibrillationCancer patientsBreast cancer stageRisk factorsBreast cancerCardiovascular mortalityCancer stageCancer diagnosisAF incidenceBreast cancer-related mortalityDevelopment of AFCox proportional hazards modelNew primary diagnosisOnset atrial fibrillationRisk survival statisticsSEER-Medicare analysisCardiovascular risk factorsEnd Results-MedicarePrevalent atrial fibrillationKaplan-Meier methodUnited States cohortCancer-related mortalityPatient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.Peer-Reviewed Original ResearchConceptsOvarian function suppressionPositive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerBreast cancerPremenopausal womenPatient preferencesPremenopausal Hormone Receptor-Positive Breast CancerAdjuvant gonadotropin‐releasing hormone analoguesHR-positive breast cancerGonadotropin-releasing hormone analogueDiscontinuation of GnRHaThird of patientsChi-square testMonthly goserelinClinical characteristicsTreatment toxicityVaginal drynessClinicopathologic characteristicsGnRH analoguesHot flashesSurgical ablationResultsA totalMedical recordsGnRHaEffects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic review
Addison S, Shirima D, Aboagye-Mensah EB, Dunovan SG, Pascal EY, Lustberg MB, Arthur EK, Nolan TS. Effects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic review. Journal Of Cancer Survivorship 2021, 16: 1023-1046. PMID: 34357555, PMCID: PMC8342979, DOI: 10.1007/s11764-021-01094-8.Peer-Reviewed Original ResearchConceptsHealth-related outcomesCognitive behavioral therapyCancer survivorsUsual careHL interventionsBehavioral therapyTandem interventionsBreast cancer survivorsHealthy lifestyle interventionUse of CBTCancer-related effectsLifestyle interventionAdvanced cancerLifestyle behaviorsEmbase databasesInclusion criteriaEfficacious interventionsSystematic reviewComprehensive searchCancer treatmentSurvivorsAdverse effectsInterventionOutcomesPaucity of knowledge